INTRODUCTION {#sec1-1}
============

Prostate cancer is a common cause of cancer death in men that is potentially curable when it has not metastasized. High-risk disease (clinical stage T2c, Gleason score \>8, and prostate-specific antigen (PSA) \>20 ng/ml),\[[@ref1]\] is more often associated with metastases especially to lymph nodes and bones. ^99m^Tc-MDP bone scan is the most commonly used modality to assess for skeletal metastases in prostate cancer. However, if magnetic resonance imaging (MRI) is done, usually for defining the local extent of disease, it is more sensitive and specific for bone metastases than bone scan.\[[@ref2]\] Gallium-68 prostate-specific membrane antigen (^68^Ga-PSMA) is a new positron emission tomography-computed tomography (PET-CT) tracer that has shown high sensitivity and specificity for local disease, lymph node metastases, and bone metastases. We present a case of high-risk prostate cancer with false positive skeletal metastases on MRI as confirmed by histology which was truly negative on bone scan and ^68^Ga-PSMA PET-CT.

CASE REPORT {#sec1-2}
===========

A 53-year-old man was referred from a peripheral hospital with high-risk prostate cancer, clinical stage T2c, Gleason 4 + 5, and PSA of 103 ng/ml. He had a ^99m^Tc-MDP bone scan which was negative for skeletal metastases \[[Figure 1](#F1){ref-type="fig"}\]. He was considered for radical surgery and was, therefore, sent for pelvic MRI to define the local extent of disease and ^68^Ga-PSMA PET-CT to assess for distant metastases given the high PSA level. The MRI and ^68^Ga-PSMA PET-CT were acquired about 1 week apart. MRI showed inhomogeneous marrow signal with numerous low signal lesions on T1- and T2-weighted images in the pelvic bones consistent with skeletal metastases \[[Figure 2](#F2){ref-type="fig"}\]. There were no skeletal metastases on ^68^Ga-PSMA PET-CT in the pelvis or any other bone \[[Figure 3](#F3){ref-type="fig"}\]. Bone marrow biopsy was done because of the discordant finding on the MRI and ^68^Ga-PSMA PET-CT. Histology showed normal bone marrow with no evidence of malignancy \[[Figure 4](#F4){ref-type="fig"}\].

![Bone scan shows no evidence of skeletal metastasis](WJNM-17-305-g001){#F1}

![Transaxial T1-weighted and coronal T2-weighted magnetic resonance imaging images show numerous low signal lesions in the pelvic bones consistent with skeletal metastases](WJNM-17-305-g002){#F2}

![^68^Ga-PSMA PET-CT images show no evidence of skeletal metastasis](WJNM-17-305-g003){#F3}

![H and E, ×200 objective shows normal marrow (a). Negative AE 1/3 immunohistochemistry (b)](WJNM-17-305-g004){#F4}

DISCUSSION {#sec1-3}
==========

Prostate cancer is the most common malignancy after middle age and the third-most common cause of cancer death in men.\[[@ref3][@ref4]\] Clinical risk stratification is based on findings on digital rectal examination, Gleason grade, and PSA level. The disease extent, localized or metastatic, is assessed with imaging. Metastatic disease is more common in high-risk patients. Prostatectomy in addition to other forms of treatment may be offered to patients with localized disease whereas patients with metastases are not offered prostatectomy.\[[@ref4][@ref5]\] Bone is the second-most common site of prostate cancer metastases after lymph nodes, and ^99m^Tc-MDP bone scintigraphy which is most commonly used for assessing skeletal metastases has a lower sensitivity and specificity compared to whole-body MRI (79% vs. 97% and 82% vs. 95%).\[[@ref2]\] Whole body MRI is however often impracticable. In prostate cancer, MRI is used to define the local extent of disease and assess invasion into surrounding structures.^68^ Ga-PSMA PET-CT is an emerging modality that enables imaging of PSMA which is overexpressed in the primary lesion and metastases.\[[@ref6][@ref7]\] The expression of PSMA at the primary site and in metastatic lesions is directly related to the aggressiveness of the prostate cancer.\[[@ref8]\] ^68^Ga-PSMA PET-CT is highly sensitive for nodal and skeletal metastases. The role of ^68^Ga-PSMA PET-CT in prostate cancer is still evolving. Currently, it is recommended for localization of tumor following biochemical recurrent prostate cancer and in the staging of high-risk prostate cancer.\[[@ref9]\]

Our patient had pelvic MRI to appropriately plan for prostatectomy and had ^68^Ga-PSMA PET-CT so as to be absolutely sure there was no metastases particularly to pelvic and intra-abdominal nodes. Had a ^68^Ga-PSMA PET-CT not been done, the finding of pelvic bone metastases on MRI would have superseded the negative bone scan and the patient would not have been considered for radical treatment. The florid nature of the pelvic metastases seen on MRI was however not in keeping with a negative ^68^Ga-PSMA PET-CT. We considered that the patient may have a second malignancy responsible for the bone marrow infiltration which is not ^68^Ga-PSMA avid. Pelvic bone biopsy showed normal marrow with no evidence of malignancy.

MRI is more sensitive and specific than ^99m^Tc-MDP bone scan for skeletal metastases and patients who have just these two investigations and show skeletal metastases on MRI would be classified as having skeletal metastases irrespective of the bone scan findings.\[[@ref10]\] If ^68^Ga-PSMA PET-CT is done and negative for skeletal metastases in the setting of a positive MRI, a histologic diagnosis may be needed to avoid wrong staging of the patient which will affect the type of treatment offered. This report contributes to the data on the value of ^68^Ga-PSMA PET-CT in prostate cancer skeletal metastasis.
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